Skip to main content
Download PDF
Download ePub

Brain barriers and their potential role in migraine pathophysiology

The Journal of Headache and Pain volume 23, Article number: 16 (2022) Cite this article

Abstract

Migraine is a ubiquitous neurologic disease that afflicts people of all ages. Its molecular pathogenesis involves peptides that promote intracranial vasodilation and modulate nociceptive transmission upon release from sensory afferents of cells in the trigeminal ganglion and parasympathetic efferents of cells in the sphenopalatine ganglion. Experimental data have confirmed that intravenous infusion of these vasoactive peptides induce migraine attacks in people with migraine, but it remains a point of scientific contention whether their site of action lies outside or within the central nervous system. In this context, it has been hypothesized that transient dysfunction of brain barriers before or during migraine attacks might facilitate the passage of migraine-inducing peptides into the central nervous system. Here, we review evidence suggestive of brain barrier dysfunction in migraine pathogenesis and conclude with lessons learned in order to provide directions for future research efforts.

Introduction

Migraine is a prevalent neurological disorder that is characterized by recurrent headache attacks of moderate to severe intensity and accompanying symptoms such as nausea, vomiting, photo-, and phonophobia [1]. Its pathogenesis is to be explained within the framework of the trigeminovascular system [2]. This system includes the trigeminal ganglion and its peripheral axonal projections that innervate pain-sensitive intracranial structures, e.g. meninges [3]. In addition, central axonal projections arise from trigeminal ganglion cells and convey nociceptive impulses to second-order trigeminovascular neurons in the brain stem [3]. These neurons, in turn, project to third order trigeminovascular neurons in the thalamus, which then convey nociceptive impulses to a wide array of cortical areas that are involved in pain processing, e.g. the somatosensory cortex [3].

A point of scientific contention is whether the molecular mechanisms that initiate migraine attacks lie outside or within the central nervous system (CNS) [1]. Upon activation, peripheral projections of the trigeminal nerve release neurotransmitters that elicit vasodilation and modulate nociceptive transmission, e.g. calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) [3]. Intravenous administration of these neurotransmitters can induce migraine attacks in individuals with migraine, whereas healthy volunteers most often develop no more than mild headache [4]. Based on this, it becomes a question of key interest whether these neuropeptides can cross the blood-brain barrier (BBB) and initiate migraine attacks from within the CNS. If not, this would favor a peripheral origin of migraine.

In this Review, we examine evidence suggestive of brain barrier dysfunction in migraine. Furthermore, we discuss whether neuropeptides that induce migraine attacks have their site of action within the CNS. Lastly, we review some of the outstanding research questions and provide directions for future research efforts.

Brain barriers

The brain has multiple barriers to restrict non-selective passage of solutes into brain parenchyma [5]. In the meninges, the arachnoid barrier impedes the leakage of solutes from fenestrated blood vessels into the subarachnoid space that is filled with cerebrospinal fluid (CSF). Blood vessels in the subarachnoid space consist of endothelial cells that are connected by tight junctions with similar barrier characteristics as blood vessels in brain parenchyma but without surrounding pericytes and astrocytic end-feet [6]. This hinders passage of solutes from the blood to the CSF and is called the blood-CSF-barrier (BCSFB). The arterioles that branch from the subarachnoid blood vessels penetrate the brain parenchyma and constitute the brain microvasculature. The microvasculature is part of the BBB, a dynamic interface comprised of vascular cells (e.g. endothelium, pericytes), glial cells (e.g. astrocytes), and neurons [5,6,7].

As a rule of thumb, hydrophilic molecules of less than 620 Da cross the BBB via diffusion along the paracellular route, and small lipophilic molecules diffuse freely through the lipid membranes. However, the majority of these freely diffusing lipophilic molecules are rapidly removed from endothelial cells by efflux transporters and do not reach the brain parenchyma. All other solutes require transporters located on endothelial cells [5]. Solutes also enter the CNS via the circumventricular organs (CVOs) that are free of BBB and located near the ventricular system [8]. The CVOs include the following structures: area postrema, median eminence, pineal gland, pituitary gland, subcommissural organ, subfornical organ, and vascular organ of lamina terminalis [8]. Their leakiness allows accumulation of circulating agents, but a barrier comprised of tanycytes with tight junctions prevents the passage of agents into the CSF [6].

Blood-brain barrier dysfunction in migraine pathogenesis

The hypothesis of BBB dysfunction in migraine was first proposed by Harper and colleagues in 1977 [9]. The authors speculated that a leaky BBB allowed circulating agents in the peripheral blood to enter the CNS and facilitate transmission of nociceptive impulses that ultimately yield the perception of migraine pain. However, there is currently very limited experimental evidence in favor of this hypothesis. Three magnetic resonance imaging (MRI) studies found no evidence of a leaky BBB during and outside of spontaneous migraine attacks (Table 1) [10,11,12]. Two of the studies used gadolinium-based dynamic contrast-enhanced (DCE) MRI to assess disruption of the BBB in five regions of interest, being the anterior, middle, and posterior cerebral area, brain stem, posterior pons, and whole brain [10, 11]. Patients were scanned during a spontaneous migraine attack as well as on an attack-free day. No changes suggestive of BBB dysfunction were identified in 19 patients with migraine without aura [14] or 19 patients with migraine with aura [15] when comparing data during and outside of migraine attacks. There was also no association between BBB permeability and any headache feature (e.g., location, intensity). However, post hoc power analysis showed that BBB permeability changes of less than 35% in patients with migraine without aura and changes of less than 11% in patients with migraine with aura could not be excluded [10, 11]. Another limitation is that early and/or transient changes in BBB permeability may not have been detected, as median time from onset of attack to MRI scan was 6.5 h in patients with migraine without aura [14] and 7.6 h in patients with migraine with aura [15]. In a third DCE-MRI study, differences in BBB permeability were assessed in 35 patients with migraine with/without aura and 21 healthy non-headache controls [12]. Patients with migraine were scanned outside of attacks and the authors found no changes in BBB permeability when comparing the two groups. Although they did find a lower fractional plasma volume in the left amygdala of patients with migraine when compared with healthy controls [12], it is unclear whether this finding has any relevance to BBB dysfunction during migraine attacks.

Table 1 Human experimental studies of BBB integrity in migraine
Full size table

BBB permeability has also been assessed during provoked migraine attacks using positron emission tomography – computed tomography (PET-CT) with the radioligand 11C-dihydroergotamine (11C-DHE) (Table 1) [13]. Migraine attacks were induced by intravenous infusion of the nitric oxide donor glyceryl trinitrate (GTN) which is a potent vasodilator known to provoke migraine attacks in 80% of patients with migraine [16]. It should be noted that patients were eligible for study inclusion only if they developed a migraine attack after GTN infusion whereas subjects in the control group had to remain free of pain following GTN infusion [13]. The authors reported no changes suggestive of BBB dysfunction when comparing scans before and during provoked attacks, or when comparing scans of patients to those of controls. However, the limited spatial resolution of PET and the usage of 11C-DHE tracer (584 Da) might impede the detection of minor changes in BBB permeability [13]. Taken together, it seems evident that neuroimaging studies provide no evidence for BBB dysfunction during migraine attacks, although early transient or minor changes in BBB permeability cannot be fully excluded.

Dysfunction of the BBB has been evaluated by the activity of matrix metallopeptidases (MMPs) since some members of this protease family seem to be implicated in breakdown of the BBB [17]. In a rodent study, cortical spreading depression (CSD) led to BBB disruption and an increase in MMP-9 levels in cortical homogenates ipsilateral to the induced CSD [18]. However, CSD was induced by three pinpricks after removing large parts of the calvarium bilaterally and opening the dura mater. This procedure had evidently caused neuroinflammatory responses which, in turn, limits the significance of the study findings. Similarly, there is conflicting data from studies that have assessed plasma MMP-9 levels in human subjects. Some studies report elevated plasma MMP-9 levels in migraine patients compared with controls [14, 15] while others find no association between plasma MMP-9 levels and migraine [19, 20]. Thus, it is not possible to draw any firm conclusions based on measurements of plasma MMP-9. A few limitations should also be noted. First, MMPs are produced by various cell types inside and outside the nervous system. It is therefore unknown whether MMPs that are produced in intracerebral cells reach the peripheral circulation. Second, MMP measurements are not a specific measure of BBB dysfunction since intracerebral levels of MMP-3 and MMP-9 expression were elevated in an animal model of epileptic seizures while no changes in BBB permeability were observed [21]. Lastly, elevated levels of MMP-9 have been reported in various disorders that are not presumed to have alterations in BBB permeability, e.g. idiopathic atrial fibrillation [22] and rheumatoid arthritis [23].

An aspect that merits emphasis is the special case of migraine with aura. CSD is widely recognized as the neurobiological substrate of aura and is characterized by a self-propagating cortical wave of electrophysiological hyperactivity following by inhibition [24].

Based on animal data, it seems evident that CSD induces inflammatory processes within the brain and meninges which, in turn, appears to increase the firing rate of first and second order trigeminovascular neurons [25,26,27]. A recent PET-MRI study using the ligand 11C-PBR28 observed strong extra-axial inflammatory signals in the meninges overlying the occipital lobe during migraine with visual aura in 11 migraine patients [28]. Repetitive episodes of neuroinflammation in migraine patients could result in a leaky BBB and allow passage of neuropeptides into the brain parenchyma [29, 30]. Further studies are needed to evaluate whether CSD-induced inflammatory processes are associated with changes in brain barrier permeability.

Provoked migraine attacks

The trigeminovascular system is widely considered the anatomical and physiological substrate of migraine pathogenesis [1]. Within this framework, parasympathetic efferents of cells in the sphenopalatine ganglion and sensory afferents of cells in the trigeminal ganglion release, upon activation, various peptides that promote dilation of intracranial arteries and modulate nociceptive transmission [1]. Decades of research have established that intravenous infusion of certain naturally occurring peptides can induce migraine attacks in patients with migraine while healthy volunteers develop most often no more than a mild headache [4]. This raises the question of whether these peptides induce migraine attacks outside or within the CNS.

The following peptides have been implicated in migraine pathogenesis [31]: adrenomedullin (ADM), amylin, calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), and vasoactive intestinal polypeptide (VIP). All are potent vasodilators and induce migraine attacks when administered by intravenous infusion to patients with migraine [31, 32]. They mediate their effects via G protein-coupled receptors that, in turn, activate the cyclic adenosine monophosphate (cAMP)-dependent signaling pathway [31]. Preclinical evidence suggests that this pathway results in the opening of ATP-sensitive potassium (KATP) channels, and it has been hypothesized that opening of potassium channels might be the final common pathway in the genesis of a migraine pain [1]. Collectively, the neuropeptides have receptor-binding sites that are expressed at multiple levels of the trigeminovascular system (Table 2) of which the extracerebral vasculature, extracranial vasculature and the trigeminal ganglion is not brain barrier protected.

Table 2 Receptor binding sites within the trigeminovascular system. The table gives an overview of seven different migraine-inducing substances and their various binding sites within the trigeminovascular system. In this table, the trigeminovascular system is divided into the following structures: extracranial vasculature, intracranial vasculature, the trigeminal ganglion, the spinal trigeminal nucleus, and thalamus. The binding sites have been detected by usage of polymerase chain reaction, in-situ hybridization, western blot, or immunostaining in human , monkey , pig , or rodent tissues
Full size table

Direct binding of neuropeptides to Aδ-fibers or neurons in the trigeminal ganglion and subsequent hyperexcitability has been suggested as the pain-initiating mechanism in migraine. However, based on the suggested intracellular pathway with KATP channels as the end station direct binding to nerve fibers would result in hyperpolarization, and thus the vasculature might be a more relevant site of action. Other ganglia without barrier protection may also be involved in migraine pathogenesis, and preclinical data has suggested that activation of the sphenopalatine ganglion causes release of PACAP and VIP from its efferent fibers [1]. This mechanism is bypassed in provoked migraine attacks where the neuropeptides are given intravenously but could play a role in spontaneous attacks. It merits emphasis that ADM, amylin, and CGRP belong to the same family of peptides [33]. The same is also true for PACAP and VIP [34].

The molecular size of the aforementioned peptides suggests a very limited ability to cross the brain barrier (Table 3) [5]. This accords with animal studies that have radiolabeled all peptides, except for CGRP, and quantified the degree of BBB passage [40, 41, 43, 50, 69,70,71]. In rodents, injection of radiolabeled ADM does not cross the BBB [69], whilst the peak brain uptake of injected radiolabeled amylin is 0.11–0.13% [40, 70]. Furthermore, injection of radiolabeled PACAP yields a brain uptake of less than 0.07% in rodents for both its isoforms (i.e. PACAP-38 and PACAP-27) [43], while injection of radiolabeled VIP results in brain uptake of 0.15% in mice and no brain uptake in rats [41, 50].

Table 3 Brain Barrier Permeability of Migraine-Inducing Substances
Full size table

Another method to investigate possible brain barrier passage of migraine-inducing peptides involves the study of their vascular responses. In this context, dilation of the middle cerebral artery (MCA) has often been used as a surrogate marker of BBB penetration. The MCA is surrounded by the BCSFB and branches into smaller vessels that penetrate the brain parenchyma. These small vessels are surrounded by the BBB and constitute the cerebral microvasculature. Based on this, it is assumed that lack of MCA dilation by migraine-inducing peptides would suggest no or very limited BBB passage. This, in turn, would indicate that the site of action of migraine-inducing peptides is located outside of the CNS.

The vascular responses of migraine-inducing peptides have been extensively studied in vitro using rodent or human MCA. These studies have found that ADM, CGRP, both PACAP isoform, and VIP did not elicit dilation of the rat MCA following luminal application [35, 45, 48, 59], whilst amylin induced only a weak dilator response [71]. Furthermore, luminal application of both PACAP isoforms and VIP did not evoke dilation of the human MCA [45, 71]. Although these preclinical studies provide evidence against a central side of action of migraine-inducing substances, it should be recognized that tissue preparation can affect transporters located in the endothelium which, in turn, might affect tissue permeability.

This issue is avoided when assesing vasodilation in vivo by using ultrasound or magnetic resonance angiography (MRA). Ultrasound of brain arteries detects changes in blood velocity, a factor inversely proportional to the diameter of the blood vessel. Since the blood flow is also dependent on the vascular diameter, a decrease in MCA velocity only reflects vasodilation if the single photon-emission computed tomography (SPECT)-determined regional cerebral blood flow (rCBF) is unchanged [54].

A decrease in ultrasound assessed MCA velocity and no change in SPECT-determined rCBF has been reported after CGRP and VIP infusion [36, 51] whereas infusion of ADM did not affect any of the two parametres [39]. This suggests CGRP- and VIP-induced vasodilation of the MCA and possibly BCSFB passage. A decrease in MCA velocity was also reported after infusion of PACAP-38, and PACAP-38 has previously been reported not to affect rCBF in healthy volunteers [47, 72]. Although some of the ultrasound-based studies indicate BCSFB permeability, the results should be interpreted with caution since this method assesses vasodilation indirectly.

MRA enables visualization of extra- and intracerebral arteries and direct measurement of arterial circumferences. MRA studies performed on healthy controls and migraine patients report dilation of the MMA after infusion of CGRP, PACAP-27, PACAP-38, and VIP but no change of the MCA circumference [37, 46, 49, 53, 73]. This is consistent with no BCSFB passage and suggestive of a peripheral site of action. Lack of brain barrier permeability of the neuropeptides might also explain the lack of CNS side effects in human experimental studies with intravenous infusion of migraine-inducing peptides. It should also be noted that CGRP infusion did not modulate blood-oxygen-level-dependent (BOLD) responses in the visual cortex of healthy volunteers which is consistent with no or very limited passage of CGRP across the BBB [74]. Taken together, the available experimental data favors the assertion that migraine-inducing neuropeptides bind to their receptors outside of the BBB.

Therapies targeting CGRP-signaling

The recent advent of small molecule CGRP receptor antagonists, gepants, and monoclonal antibodies (mAbs) targeting CGRP or its receptor have expanded the therapeutic armamentarium for migraine. Important questions have since been raised on whether these drugs can cross the BBB and exert their therapeutic effects from within the CNS [75]. This seems unlikely based on the available data from an in vivo PET study in which the authors reported very low human CGRP receptor occupancy following administration of telcagepant at an efficacious dose – suggestive of a peripheral site of action for telcagepant [76]. This finding accords well with the observation of reduced mechanical sensitivity thresholds in rodents following intraperitoneal, but not intracerebroventricular, injection of olcegepant and a mAb against CGRP [77]. Furthermore, intravenous injection of fluorescently-labeled fremanezumab yielded labeling of sensory and autonomic ganglia as well as the dura mater, whereas no fluorescent signal was observed in structures within the CNS [78].

Collectively, it seems evident that therapies targeting CGRP signaling are unlikely to cross the BBB which, in turn, indicates that BBB passage is not needed to achieve therapeutic benefits with medications for migraine. It might indeed be advisable to develop drugs that do not cross the BBB to avoid adverse effects associated with CNS depression. For example, lasmiditan (serotonin (5-HT) 1F receptor agonist) is an acute medication for migraine that can cause CNS-related side effects (incl. Dizziness, sedation, and temporary driving impairment) which are likely to limit its use in clinical practice [79,80,81].

Outstanding research questions

The current evidence obtained from both neuroimaging and biochemical markers in humans suggests no disruption of the brain barriers in migraine. However, the limited sensitivity of the applied methods requires more studies to assess the relationship between brain barrier dysfunction and migraine pathophysiology. Future studies could use the newly developed sensitive modified DCE-MRI method that considers the arterial input function and cerebral blood flow [82] since both these parameters could be affected in migraine. This method has identified BBB dysfunction in early stages of cognitive dysfunction [82]. Additionally, soluble PDGFRβ, a biomarker of BBB pericyte injury, could be analyzed in migraine patients [83].

The limited brain barrier passage of migraine-inducing neuropeptides suggests a peripheral origin of migraine. However, migraine attacks can also be induced in migraine patients by administration of vasoactive molecules with BBB permeability (e.g. GTN or cilostazol [16, 61, 62]), and several questions concerning migraine origin remain unanswered. One of them is the presence of premonitory symptoms (PS) in migraine which might be suggestive of initial activation of central structures in migraine attacks. The underlying mechanisms of PS are still unclear. Infusion of GTN to migraine patients induced PS in 36% (12/33) of patients prior to triggered migraine attacks [84]. In another study, GTN was found to induce PS in a selected group of patients known to have migraine with PS while PET-scans showed activation in various different brain areas, including hypothalamus [85]. In this study, however, no control group was included, and thus changes may relate to GTN administration rather than migraine. Furthermore, none of these studies compared PS in patients who reported and did not report migraine attacks. A study assessing the incidence of PS in migraine patients after administration of trigeminal signaling molecules reported no PS after CGRP infusion but PS in 48% of patients after PACAP-38 infusion [86]. However, CGRP and PACAP38 did not induce more PS in patients who developed an attack compared to those who did not develop an attack [86], and this aspect must be studied in healthy subjects. Further studies are needed to clarify the presence of a premonitory phase in migraine which may contribute to the discussion of migraine origin.

Additionally, several outstanding questions relate to migraine aura. Although CSD is accepted as the substrate of migraine aura, it is still unknown how CSD arises in a seemingly otherwise healthy cerebral cortex of migraine patients, and how it is related to the headache phase of migraine. The unpredictable and short-lasting nature of migraine aura makes it difficult to study patients during symptoms and thereby answer outstanding research questions on this matter. However, recently a randomized, double-blind, placebo-controlled, crossover study reported that administration of the KATP-channel opener levcromakalim induced aura in 10 of 17 (59%) patients suffering from migraine with aura and migraine attacks in 14 of 17 (82%) the patients [87]. The authors suggest that KATP-channel opening most likely induces CSD and migraine headache via separate pathways since levcromakalim efficiently triggers migraine without aura [65] and this even in some patients who have previously experienced aura symptoms during all their migraine attacks [87]. However, the trigger of migraine aura is still unknown and future research efforts are required to fully understand the initiation CSD and its relation to the headache phase of migraine.

Conclusion

Brain barrier disruption has been hypothesized to play an important role in the genesis of migraine attacks. The current evidence suggests, however, that there is limited experimental data in favor of this hypothesis. Nonetheless, it cannot be excluded that, in particular, CSD might be associated with inflammatory processes within the brain and meninges, ultimately causing transient brain barrier disruption. Further studies are warranted to ascertain whether early transient changes in BBB permeability occur during the early phases of a migraine attack.

Availability of data and materials

Not applicable.

Abbreviations

CNS:

Central nervous system

CGRP:

Calcitonin gene-related peptide

PACAP:

Pituitary adenylate cyclase-activating peptide

BBB:

Blood-brain barrier

CSF:

Cerebrospinal fluid

BCSFB:

Blood-cerebrospinal fluid barrier

CVO:

Circumventricular organs

MRI:

Magnetic resonance imaging

DCE MRI:

Dynamic contrast-enhanced magnetic resonance imaging

PET-CT:

Position emission tomography-computed tomography

GTN:

Glyceryl trinitrate

11C-DHE:

11C-Dihydroergotamine

MMP:

Matrix metallopeptidase

CSD:

Cortical spreading depression

ADM:

Adrenomedullin

VIP:

Vasoactive intestinal peptide

cAMP:

Cyclic adenosine monophosphate

KATP :

ATP-sensitive potassium channel

MCA:

Middle cerebral artery

MRA:

Magnetic angiography

SPECT:

Single-photon emission computerized tomography

rCBF:

Regional cerebral blood flow

BOLD:

Blood-oxygen-level-dependent

PS:

Premonitory symptoms

mAb:

monoclonal antibody

References

  1. Ashina M, Ropper AH (2020) Migraine. N Engl J Med 383(19):1866–1876. https://doi.org/10.1056/NEJMra1915327

    Article  CAS  PubMed  Google Scholar 

  2. Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16(2):157–168. https://doi.org/10.1002/ana.410160202

    Article  CAS  PubMed  Google Scholar 

  3. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol 18(8):795–804. https://doi.org/10.1016/s1474-4422(19)30185-1

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ashina M, Hansen JM, BO AD, Olesen J. (2017) Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol 13(12):713–724. https://doi.org/10.1038/nrneurol.2017.137

    Article  PubMed  Google Scholar 

  5. Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15(4):275–292. https://doi.org/10.1038/nrd.2015.21

    Article  CAS  PubMed  Google Scholar 

  6. Saunders NR, Dziegielewska KM, Møllgård K, Habgood MD (2018) Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain. J Physiol 596(23):5723–5756. https://doi.org/10.1113/JP275376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kutuzov N, Flyvbjerg H, Lauritzen M (2018) Contributions of the glycocalyx, endothelium, and extravascular compartment to the blood–brain barrier. Proc Natl Acad Sci U S A 115(40):E9429–E9438. https://doi.org/10.1073/pnas.1802155115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ermisch A, Brust P, Kretzschmar R, Rühle HJ (1993) Peptides and blood-brain barrier transport. Physiol Rev 73(3):489–527. https://doi.org/10.1152/physrev.1993.73.3.489

    Article  CAS  PubMed  Google Scholar 

  9. Harper AM, MacKenzie ET, McCulloch J, Pickard JD (1977) Migraine and the blood-brain barrier. Lancet. 1(8020):1034–1036. https://doi.org/10.1016/s0140-6736(77)91262-4

    Article  CAS  PubMed  Google Scholar 

  10. Amin FM, Hougaard A, Cramer SP, Christensen CE, Wolfram F, Larsson HBW, Ashina M (2017) Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur J Neurol 24(9):1116–1124. https://doi.org/10.1111/ene.13341

    Article  CAS  PubMed  Google Scholar 

  11. Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP, Larsson HBW, Ashina M (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 140(6):1633–1642. https://doi.org/10.1093/brain/awx089

    Article  PubMed  Google Scholar 

  12. Kim YS, Kim M, Choi SH, You SH, Yoo RE, Kang KM, Yun TJ, Lee ST, Moon J, Shin YW (2019) Altered vascular permeability in migraine-associated brain regions: evaluation with dynamic contrastenhanced MRI. Radiology. 292(3):713–720. https://doi.org/10.1148/radiol.2019182566

    Article  PubMed  Google Scholar 

  13. Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, VanBrocklin HF, Goadsby PJ (2016) Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 139(Pt 7):1994–2001. https://doi.org/10.1093/brain/aww096

    Article  PubMed  PubMed Central  Google Scholar 

  14. Leira R, Sobrino T, Rodríguez-Yáñez M, Blanco M, Arias S, Castillo J (2007) MMP-9 immunoreactivity in acute migraine. Headache. 47(5):698–702. https://doi.org/10.1111/j.1526-4610.2006.00641.x

    Article  PubMed  Google Scholar 

  15. Imamura K, Takeshima T, Fusayasu E, Nakashima K (2008) Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 48(1):135–139. https://doi.org/10.1111/j.1526-4610.2007.00958.x

    Article  PubMed  Google Scholar 

  16. Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1(1):73–80. https://doi.org/10.1111/j.1468-1331.1994.tb00053.x

    Article  CAS  PubMed  Google Scholar 

  17. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893(1–2):104–112. https://doi.org/10.1016/S0006-8993(00)03294-7

    Article  CAS  PubMed  Google Scholar 

  18. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113(10):1447–1455. https://doi.org/10.1172/jci21227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, Tanus-Santos JE (2009) Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 408(1–2):60–64. https://doi.org/10.1016/j.cca.2009.07.008

    Article  CAS  PubMed  Google Scholar 

  20. Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J (2010) Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia. 30(3):303–310. https://doi.org/10.1111/j.1468-2982.2009.01954.x

    Article  CAS  PubMed  Google Scholar 

  21. Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J (2005) Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res 79(4):522–534. https://doi.org/10.1002/jnr.20387

    Article  CAS  PubMed  Google Scholar 

  22. Li M, Yang G, Xie B, Babu K, Huang C (2014) Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation. J Int Med Res 42(1):224–230. https://doi.org/10.1177/0300060513488514

    Article  CAS  PubMed  Google Scholar 

  23. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78(2):161–171. https://doi.org/10.1006/clin.1996.0025

    Article  CAS  PubMed  Google Scholar 

  24. Lauritzen M (1994) Pathophysiology of the migraine aura: the spreading depression theory. Brain. 117(1):199–210. https://doi.org/10.1093/brain/117.1.199

    Article  PubMed  Google Scholar 

  25. Karatas H, Erdener SE, Gursoy-Ozdemir Y et al (2013) Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339(6123):1092–1095. https://doi.org/10.1126/science.1231897

    Article  CAS  PubMed  Google Scholar 

  26. Zhang XC, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R (2010) Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 30(26):8807–8814. https://doi.org/10.1523/JNEUROSCI.0511-10.2010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhang XC, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R (2011) Activation of central TGV neurons by CSD. Ann Neurol 69(5):855–865. https://doi.org/10.1002/ana.22329.Activation

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hadjikhani N, Albrecht DS, Mainero C, Ichijo E, Ward N, Granziera C, Zürcher NR, Akeju O, Bonnier G, Price J, Hooker JM, Napadow V, Nahrendorf M, Loggia ML, Moskowitz MA (2020) Extra-axial inflammatory signal in Parameninges in migraine with visual Aura. Ann Neurol 87(6):939–949. https://doi.org/10.1002/ana.25731

    Article  PubMed  PubMed Central  Google Scholar 

  29. Liktor-Busa E, Blawn KT, Kellohen KL et al (2020) Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake. PLoS One 15(5):e0227463. https://doi.org/10.1371/journal.pone.0227463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ghaffari H, Grant SC, Petzold LR, Harrington MG (2020) Regulation of CSF and brain tissue sodium levels by the blood-CSF and blood-brain barriers during migraine. Front Comput Neurosci 14:4. https://doi.org/10.3389/FNCOM.2020.00004

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ashina M, Terwindt GM, Al-Karagholi MA-M et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397(10283):1496–1504. https://doi.org/10.1016/S0140-6736(20)32162-0

    Article  CAS  PubMed  Google Scholar 

  32. Pellesi L, Al-Karagholi MA-M et al (2021) Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches A Randomized Clinical Trial. JAMA Netw Open 4(8):2118543. https://doi.org/10.1001/jamanetworkopen.2021.18543

    Article  Google Scholar 

  33. Hendrikse ER, Bower RL, Hay DL, Walker CS (2019) Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia. 39(3):403–419. https://doi.org/10.1177/0333102418765787

    Article  PubMed  Google Scholar 

  34. Sundrum T, Walker CS (2017) Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: Implications for migraine. Br J Pharmacol 175(21):4109–4120

    Article  Google Scholar 

  35. Edvinsson L, Nilsson E, Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP 8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150(5):633–640. https://doi.org/10.1038/sj.bjp.0707134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P (2008) Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 9(3):151–157. https://doi.org/10.1007/s10194-008-0036-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, van der Koning P, Larsson HBW, Olesen J, Ashina M (2010) Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 75(17):1520–1526. https://doi.org/10.1212/WNL.0b013e3181f9626a

    Article  CAS  PubMed  Google Scholar 

  38. Ghanizada H, Al-Mahdi Al-Karagholi M, Arngrim N et al (2021) Effect of Adrenomedullin on migraine-like attacks in patients with migraine. Neurology. 96(20):e2488–e2499. https://doi.org/10.1212/wnl.0000000000011930

    Article  PubMed  Google Scholar 

  39. Petersen KA, Birk S, Kitamura K, Olesen J (2009) Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia. 29(1):23–30. https://doi.org/10.1111/j.1468-2982.2008.01695.x

    Article  CAS  PubMed  Google Scholar 

  40. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB (1995) Permeability of the blood-brain barrier to amylin. Life Sci 57(22):1993–2001. https://doi.org/10.1016/0024-3205(95)02197-Q

    Article  CAS  PubMed  Google Scholar 

  41. Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M (2003) Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides. 24(3):437–444. https://doi.org/10.1016/S0196-9781(03)00059-7

    Article  CAS  PubMed  Google Scholar 

  42. Ghanizada H, Al-Karagholi MAM, Walker CS et al (2021) Amylin analog Pramlintide induces migraine-like attacks in patients. Ann Neurol 89(6):1157–1171. https://doi.org/10.1002/ana.26072

    Article  CAS  PubMed  Google Scholar 

  43. Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood- brain barrier. J Pharmacol Exp Ther 267(2):690–696

    CAS  PubMed  Google Scholar 

  44. Ghanizada H, Al-Karagholi MA, Arngrim N, Olesen J, Ashina M (2020) PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia. 40(1):57–67. https://doi.org/10.1177/0333102419864507

    Article  PubMed  Google Scholar 

  45. Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson L (2013) VIP/PACAP receptors in cerebral arteries of rat: Characterization, localization and relation to intracellular calcium. Neuropeptides 47(2):85–92. https://doi.org/10.1016/j.npep.2012.12.005

    Article  CAS  PubMed  Google Scholar 

  46. Ghanizada H, Al-Karagholi MA, Arngrim N et al (2019) Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: a 3T MRI study. Peptides. 121:170134. https://doi.org/10.1016/j.peptides.2019.170134

    Article  CAS  PubMed  Google Scholar 

  47. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 132(1):16–25. https://doi.org/10.1093/brain/awn307

    Article  PubMed  Google Scholar 

  48. Grände G, Labruijere S, Haanes KA, MaassenVanDenBrink A, Edvinsson L (2014) Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. J Headache Pain. 15(1):22. https://doi.org/10.1186/1129-2377-15-22

    Article  PubMed  PubMed Central  Google Scholar 

  49. Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJH, Andersen MR, Larsson HBW, Fahrenkrug J, Olesen J, Ashina M (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 137(3):779–794. https://doi.org/10.1093/brain/awt369

    Article  PubMed  Google Scholar 

  50. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM (2003) Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255(1–2):87–97. https://doi.org/10.1016/S0378-5173(03)00039-5

    Article  CAS  PubMed  Google Scholar 

  51. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, Olesen J, Ashina M (2006) Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. 26(8):992–1003. https://doi.org/10.1111/j.1468-2982.2006.01149.x

    Article  CAS  PubMed  Google Scholar 

  52. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 28(3):226–236. https://doi.org/10.1111/j.1468-2982.2007.01497.x

    Article  CAS  PubMed  Google Scholar 

  53. Pellesi L, Al-Karagholi MA, Chaudhry BA et al (2020) Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia 40(11):1223. https://doi.org/10.1177/0333102420937655

    Article  Google Scholar 

  54. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K (1989) Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke. 20(12):1733–1736. https://doi.org/10.1161/01.str.20.12.1733

    Article  CAS  PubMed  Google Scholar 

  55. Schulz JM, Al-Khazraji BK, Shoemaker JK (2018) Sodium nitroglycerin induces middle cerebral artery vasodilatation in young, healthy adults. Exp Physiol 103(8):1047–1055. https://doi.org/10.1113/EP087022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Schoonman GG, Van Der Grond J, Kortmann C, Van Der Geest RJ, Terwindt GM, Ferrari MD (2008) Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain. 131(8):2192–2200. https://doi.org/10.1093/brain/awn094

    Article  CAS  PubMed  Google Scholar 

  57. Gómez-Vallejo V, Ugarte A, García-Barroso C, Cuadrado-Tejedor M, Szczupak B, Dopeso-Reyes IG, Lanciego JL, García-Osta A, Llop J, Oyarzabal J, Franco R (2016) Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. J Neurochem 136(2):403–415. https://doi.org/10.1111/jnc.13454

    Article  CAS  PubMed  Google Scholar 

  58. Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J (2003) Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia 24(7):547–553

    Article  Google Scholar 

  59. Grände G, Nilsson E, Edvinsson L (2013) Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia. 33(3):152–159. https://doi.org/10.1177/0333102412468340

    Article  PubMed  Google Scholar 

  60. Kruuse C, Gupta S, Nilsson E, Kruse L, Edvinsson L (2012) Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. Eur J Pharmacol 674(2–3):345–351. https://doi.org/10.1016/j.ejphar.2011.10.037

    Article  CAS  PubMed  Google Scholar 

  61. Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain. 137(11):2951–2959. https://doi.org/10.1093/brain/awu244

    Article  PubMed  Google Scholar 

  62. Butt JH, Rostrup E, Hansen AS, Lambertsen KL, Kruuse C (2018) Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. Brain. 141(10):2943–2951. https://doi.org/10.1093/brain/awy228

    Article  PubMed  Google Scholar 

  63. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24(12):1352–1358. https://doi.org/10.1097/01.WCB.0000143536.22131.D7

    Article  CAS  PubMed  Google Scholar 

  64. Khan S, Amin FM, Christensen CE, Ghanizada H, Younis S, Olinger ACR, de Koning PJH, Larsson HBW, Ashina M (2019) Meningeal contribution to migraine pain: a magnetic resonance angiography study. Brain. 142(1):93–102. https://doi.org/10.1093/brain/awy300

    Article  PubMed  Google Scholar 

  65. Al-Karagholi MA, Hansen JM, Guo S, Olesen J, Ashina M (2019) Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain. 142(9):2644–2654. https://doi.org/10.1093/brain/awz199

    Article  PubMed  Google Scholar 

  66. Al-Karagholi MAM, Ghanizada H, Nielsen CAW et al (2020) Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers. J Cereb Blood Flow Metab 41(6):1328–1337. https://doi.org/10.1177/0271678X20959294

    Article  PubMed  PubMed Central  Google Scholar 

  67. Al-Karagholi MA, Ghanizada H, Waldorff Nielsen CA et al (2021) Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain 162(10):2512–2520

    CAS  PubMed  Google Scholar 

  68. Al-karagholi MA, Ghanizada H, Amalie C et al (2020) Opening of BK Ca channels alters cerebral hemodynamic and causes headache in healthy volunteers. Cephalalgia 40(11):1145–1154. https://doi.org/10.1177/0333102420940681

    Article  PubMed  Google Scholar 

  69. Kastin AJ, Akerstrom V, Hackler L, Pan W (2001) Adrenomedullin and the blood-brain barrier. Horm Metab Res 33(1):19–25. https://doi.org/10.1055/s-2001-12621

    Article  CAS  PubMed  Google Scholar 

  70. Banks WA, Kastin AJ (1998) Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides. 19(5):883–889. https://doi.org/10.1016/S0196-9781(98)00018-7

    Article  CAS  PubMed  Google Scholar 

  71. Amin FM, Schytz HW (2018) Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. J Headache Pain. 19(1):35. https://doi.org/10.1186/s10194-018-0861-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140(3):185–191. https://doi.org/10.1016/j.regpep.2006.12.010

    Article  CAS  PubMed  Google Scholar 

  73. Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJH, Larsson HBW, Olesen J, Ashina M (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 32(2):140–149. https://doi.org/10.1177/0333102411431333

    Article  PubMed  Google Scholar 

  74. Asghar MS, Hansen AE, Larsson HBW, Olesen J, Ashina M (2012) Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain 13(2):159–166. https://doi.org/10.1007/s10194-011-0415-4

    Article  PubMed  PubMed Central  Google Scholar 

  75. de Vries T, Villalón CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 211:107528. https://doi.org/10.1016/j.pharmthera.2020.107528

    Article  CAS  PubMed  Google Scholar 

  76. Hostetler ED, Joshi AD, Sanabria-Bohórquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O’Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, de Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, van Laere K, Evelhoch JL (2013) In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther 347(2):478–486. https://doi.org/10.1124/jpet.113.206458

    Article  CAS  PubMed  Google Scholar 

  77. Christensen SL, Ernstsen C, Olesen J, Kristensen DM (2020) No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia. 40(9):924–934. https://doi.org/10.1177/0333102420914913

    Article  PubMed  Google Scholar 

  78. Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F, Strassman AM, Burstein R (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia. 40(3):229–240. https://doi.org/10.1177/0333102419896760

    Article  PubMed  Google Scholar 

  79. Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501–514. https://doi.org/10.1038/S41582-021-00509-5

    Article  PubMed  PubMed Central  Google Scholar 

  80. Pearlman EM, Wilbraham D, Dennehy EB et al (2020) Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 35(5):e2732. https://doi.org/10.1002/HUP.2732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Clemow DB, Johnson KW, Hochstetler HM et al (2020) Lasmiditan mechanism of action - review of a selective 5-HT 1F agonist. J Headache Pain 21(1):71. https://doi.org/10.1186/S10194-020-01132-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV (2015) Blood-brain barrier breakdown in the aging human Hippocampus. Neuron. 85(2):296–302. https://doi.org/10.1016/J.NEURON.2014.12.032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Nation DA, Sweeney MD, Montagne A, Sagare AP, D’Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV (2019) Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 25(2):270–276. https://doi.org/10.1038/S41591-018-0297-Y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Afridi SK, Kaube H, Goadsby PJ (2004) Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 110(3):675–680. https://doi.org/10.1016/j.pain.2004.05.007

    Article  CAS  PubMed  Google Scholar 

  85. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 137(Pt 1):232–241. https://doi.org/10.1093/brain/awt320

    Article  PubMed  Google Scholar 

  86. Guo S, Vollesen ALH, Olesen J, Ashina M (2016) Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain. 157(12):2773–2781. https://doi.org/10.1097/j.pain.0000000000000702

    Article  CAS  PubMed  Google Scholar 

  87. Al-Karagholi MA-M, Ghanizada H, Nielsen CAW, Hougaard A, Ashina M (2021) Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain. 2021(8):2322–2332. https://doi.org/10.1093/brain/awab136

    Article  Google Scholar 

  88. Oliver KR, Wainwright A, Edvinsson L, Pickard JD, Hill RG (2002) Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22(5):620–629. https://doi.org/10.1097/00004647-200205000-00014

    Article  CAS  PubMed  Google Scholar 

  89. Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K (2008) Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507(3):1277–1299. https://doi.org/10.1002/cne.21607

    Article  CAS  PubMed  Google Scholar 

  90. Edvinsson JCA, Warfvinge K, Krause DN, Blixt FW, Sheykhzade M, Edvinsson L, Haanes KA (2019) C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain. 20(1):105. https://doi.org/10.1186/s10194-019-1055-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, Hay DL (2015) A second trigeminal CGRP receptor: function and expression of the AMY<inf>1</inf> receptor. Ann Clin Transl Neurol 2(6):595–608. https://doi.org/10.1002/acn3.197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Tschopp FA, Henke H, Petermann JB, Tobler PH, Janzer R, Hokfelt T, Lundberg JM, Cuello C, Fischer JA (1985) Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci U S A 82(1):248–252. https://doi.org/10.1073/pnas.82.1.248

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Stachniak TJE, Krukoff TL (2003) Receptor activity modifying protein 2 distribution in the rat central nervous system and regulation by changes in blood pressure. J Neuroendocrinol 15(9):840–850. https://doi.org/10.1046/j.1365-2826.2003.01064.x

    Article  CAS  PubMed  Google Scholar 

  94. Hensley K, Pretorius J, Chan B (2018) PAC1 receptor mRNA and protein distribution in rat and human trigeminal and sphenopalatine ganglia, spinal trigeminal nucleus and in dura mater. Cephalalgia 39(7):1–14. https://doi.org/10.1177/0333102418821621

    Article  Google Scholar 

  95. Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christophersen DV, Olesen J (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides. 48(2):53–64. https://doi.org/10.1016/j.npep.2014.01.004

    Article  CAS  PubMed  Google Scholar 

  96. Jolivel V, Basille M, Aubert N, de Jouffrey S, Ancian P, le Bigot JF, Noack P, Massonneau M, Fournier A, Vaudry H, Gonzalez BJ, Vaudry D (2009) Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates. Neuroscience. 160(2):434–451. https://doi.org/10.1016/j.neuroscience.2009.02.028

    Article  CAS  PubMed  Google Scholar 

  97. Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 476(4):388–413. https://doi.org/10.1002/cne.20231

    Article  CAS  PubMed  Google Scholar 

  98. Ploug KB, Sørensen MA, Strøbech L, Klaerke DA, Hay-Schmidt A, Sheykhzade M, Olesen J, Jansen-Olesen I (2008) KATP channels in pig and human intracranial arteries. Eur J Pharmacol 601(1–3):43–49. https://doi.org/10.1016/j.ejphar.2008.10.041

    Article  CAS  PubMed  Google Scholar 

  99. Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I (2008) K ATP channel expression and pharmacological in vivo and in vitro studies of the K ATP channel blocker PNU-37883A in rat middle meningeal arteries. Br J Pharmacol 154(1):72–81. https://doi.org/10.1038/bjp.2008.86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Nui K, Saloman JL, Zhang Y, Ro JY (2011) Sex diffferences in the contribution of ATP-sensitive K+ channels in trigeminal ganglia under an acute muscle pain condition. Neuroscience 80:344–352. https://doi.org/10.1038/jid.2014.371

    Article  CAS  Google Scholar 

  101. Ploug KB, Amrutkar DV, Baun M, Ramachandran R, Iversen A, Lund TM, Gupta S, Hay-Schmidt A, Olesen J, Jansen-Olesen I (2012) K ATP channel openers in the trigeminovascular system. Cephalalgia. 32(1):55–65. https://doi.org/10.1177/0333102411430266

    Article  CAS  PubMed  Google Scholar 

  102. Dunn-Meynell AA, Rawson NE, Levin BE (1998) Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 814(1–2):41–54. https://doi.org/10.1016/S0006-8993(98)00956-1

    Article  CAS  PubMed  Google Scholar 

  103. Sausbier U, Sausbier M, Sailer CA, Arntz C, Knaus HG, Neuhuber W, Ruth P (2006) Ca2+−activated K+ channels of the BK-type in the mouse brain. Histochem Cell Biol 125(6):725–741. https://doi.org/10.1007/s00418-005-0124-7

    Article  CAS  PubMed  Google Scholar 

  104. Wulf-Johansson H, Amrutkar DV, Hay-Schmidt A, Poulsen AN, Klaerke DA, Olesen J, Jansen-Olesen I (2010) Localization of large conductance calcium-activated potassium channels and their effect on calcitonin gene-related peptide release in the rat trigemino-neuronal pathway. Neuroscience. 167(4):1091–1102. https://doi.org/10.1016/j.neuroscience.2010.02.063

    Article  CAS  PubMed  Google Scholar 

  105. Poulsen AN, Wulf H, Hay-Schmidt A, Jansen-Olesen I, Olesen J, Klaerke DA (2009) Differential expression of BK channel isoforms and β-subunits in rat neuro-vascular tissues. Biochim Biophys Acta Biomembr 1788(2):380–389. https://doi.org/10.1016/j.bbamem.2008.10.001

    Article  CAS  Google Scholar 

Download references

Funding

No funding received.

Author information

Authors and Affiliations

  1. Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600, Glostrup, Denmark

    Astrid Wiggers, Håkan Ashina & Messoud Ashina

  2. Department of Neurorehabilitation and Traumatic Brain Injury, Rigshospitalet, Kettegaards Allé 30, 2650 Hvidovre, Copenhagen, Denmark

    HÃ¥kan Ashina

  3. Martino Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, USA

    Nouchine Hadjikhani

  4. Department of Physiology and Neuroscience and the Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, 1501 San Pablo Street, California, Los Angeles, 90089, USA

    Abhay Sagare & Berislav V. Zlokovic

  5. Department of Neuroscience, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark

    Martin Lauritzen

Authors
  1. Astrid Wiggers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. HÃ¥kan Ashina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nouchine Hadjikhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abhay Sagare
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Berislav V. Zlokovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Lauritzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Messoud Ashina
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Drafting of the manuscript and graphic items: A.W., H.A. and M.A. Critical revision of intellectual. Content: N.H., A.S., B.Z. and M.L. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Messoud Ashina.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

A.W., H.A., N.H., A. S, B. Z and M. L all declare that they have no competing interests. M.A. is a consultant, speaker, or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva and a primary investigator for ongoing AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva trials. M.A. has no ownership interest and does not own stocks of any pharmaceutical company. M.A. serves as associate editor of Cephalalgia, associate editor of the Journal of Headache and Pain, and associate editor of Brain.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wiggers, A., Ashina, H., Hadjikhani, N. et al. Brain barriers and their potential role in migraine pathophysiology. J Headache Pain 23, 16 (2022). https://doi.org/10.1186/s10194-021-01365-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s10194-021-01365-w

Keywords

  • Headache
  • Trigeminovascular system
  • Blood-brain barrier
  • Aura

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us